Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity
Tübingen (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, today announced positive top-line efficacy results from its completed Phase 2a PROHEAR Study. ACOU085 is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across ...
mehr